 IRVINE, Calif., Nov. 19, 2020 GLOBE NEWSWIRE -- Tarsus Pharmaceuticals, Inc. NASDAQ: TARS, a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, today announced the appointment of Wendy L. Yarno to its Board of Directors and its audit committee. Ms. Yarno has more than 30 years of experience in the biopharmaceutical industry, as a public company director and product commercialization leader, including 26 years at Merck Co. Inc. 